Inhibiting MDM2 enhances RIPK3-mediated necroptosis and synergizes with immune checkpoint blockade therapy

iScience 2026 Open access

Read full text
Authors: Yingxin Wu, Hanyang Yu, Zongxu Zhang, Weihang Xiong, Zexian Zeng, Weili Liu, Hailin Tu, Xin Lin
DOI: 10.1016/j.isci.2026.115724
Cited by: 1
References: 46

Abstract

T cell infiltration, leading to improved tumor control. In immunologically "cold" tumor models, combining MDM2 inhibition with anti-PD-1 blockade converted tumors to a T cell-inflamed state and significantly improved therapeutic efficacy, even in p53-deficient settings. These findings identify MDM2 as a regulator of TNF-α-induced necroptosis and highlight its potential as a therapeutic target for cancer immunotherapy.

Fields of Study & Subjects

Cell death mechanisms and regulation Phagocytosis and Immune Regulation Cancer-related Molecular Pathways

Publication details

Journal / source
iScience
Publisher
Elsevier BV
Volume
29
Issue
5
Pages
115724–115724
Publication date
11 April 2026
Language
EN